Attenuation of renal injury by depleting cDC1 and by repurposing Flt3 inhibitor in anti-GBM disease.

Animals Humans Mice Anti-Glomerular Basement Membrane Disease / drug therapy CD8-Positive T-Lymphocytes / metabolism Dendritic Cells / metabolism Drug Repositioning fms-Like Tyrosine Kinase 3 / antagonists & inhibitors Kidney / metabolism Signal Transduction
Anti-GBM disease CD103(+) DCs Conventional DCs Dendritic cells Flt3 inhibitors

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
05 2023
Historique:
received: 20 11 2022
accepted: 15 03 2023
medline: 28 4 2023
pubmed: 19 3 2023
entrez: 18 3 2023
Statut: ppublish

Résumé

Previous studies found cDC1s to be protective in early stage anti-GBM disease through Tregs, but pathogenic in late stage Adriamycin nephropathy through CD8

Identifiants

DOI: 10.1016/j.clim.2023.109295 PMID: 36933629
pubmed: 36933629
pii: S1521-6616(23)00074-8
doi: 10.1016/j.clim.2023.109295
pii:
doi:

Substances chimiques

FLT3 protein, human EC 2.7.10.1
fms-Like Tyrosine Kinase 3 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109295

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Titi Chen (T)

The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; Department of Renal Medicine, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia. Electronic address: titi.chen@sydney.edu.au.

Qi Cao (Q)

The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia.

Ruifeng Wang (R)

The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; Department of Nephrology, The Second Hospital of Anhui Medical University, Anhui 230000, China.

Guoping Zheng (G)

The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia.

Farhana Azmi (F)

The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia.

Vincent W Lee (VW)

The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; Department of Renal Medicine, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia.

Yuan Ming Wang (YM)

Centre for Kidney Research, Children's Hospital at Westmead, Sydney, NSW 2145, Australia.

Hongqi Li (H)

The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; The Department of Gerontology, Anhui Provincial Hospital, the first affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.

Di Yu (D)

Faculty of Medicine, The University of Queensland Diamantina Institute, St Lucia, QLD 4072, Australia.

Natasha M Rogers (NM)

The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; Department of Renal Medicine, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia.

Stephen I Alexander (SI)

Centre for Kidney Research, Children's Hospital at Westmead, Sydney, NSW 2145, Australia.

David C H Harris (DCH)

The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia; Department of Renal Medicine, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia.

Yiping Wang (Y)

The University of Sydney, Camperdown, NSW 2006, Australia; The Westmead Institute for Medical Research, Hawkesbury Road, Westmead, NSW 2145, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Attenuation of renal injury by depleting cDC1...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Attenuation of renal injury by depleting cDC1...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Attenuation of renal injury by depleting cDC1...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladie des anticorps antimembrane basale glomérulaire › Attenuation of renal injury by depleting cDC1...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Attenuation of renal injury by depleting cDC1...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Système phagocytaire mononucléé › Cellules dendritiques › Attenuation of renal injury by depleting cDC1...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Repositionnement des médicaments › Attenuation of renal injury by depleting cDC1...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Tyrosine kinase-3 de type fms › Attenuation of renal injury by depleting cDC1...
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Rein › Attenuation of renal injury by depleting cDC1...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Attenuation of renal injury by depleting cDC1...